Aprepitant in the Treatment of Subacute Sclerosing Panencephalitis: A Randomized, Double-Blind, Placebo-Controlled Study


Oncel I., SANCAR M., KONUŞKAN B., Arioz F., TEZCAN S., ARMAN KANDIRMAZ E., ...More

PEDIATRIC NEUROLOGY, vol.110, pp.59-63, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 110
  • Publication Date: 2020
  • Doi Number: 10.1016/j.pediatrneurol.2020.05.009
  • Journal Name: PEDIATRIC NEUROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.59-63
  • Hacettepe University Affiliated: Yes

Abstract

Background: Aprepitant is a neurokinin-1 receptor antagonist approved for the treatment of chemotherapy-induced nausea. We aimed to investigate the safety and efficacy of aprepitant in patients with subacute sclerosing panencephalitis.